Table 3 Association of complicating and concurrent comorbidities with the number of drugs used and type and volume of medical healthcare use
OutcomevariableMaindeterminantAllGPDNSMS
β (95% CI)pValueβ (95% CI)pValueβ (95% CI)pValueβ (95% CI)pValue
Total drugs usedComplicating*0.49 (0.40 to 0.58)<0.0010.63 (0.41 to 0.85)<0.0010.60 (0.42 to 0.79)<0.0010.47 (0.32 to 0.63)<0.001
Concurrent†0.57 (0.42 to 0.72)<0.0010.56 (0.25 to 0.86)<0.0010.55 (0.30 to 0.79)<0.0010.55 (0.29 to 0.80)<0.001
Specialties involvedComplicating*0.31 (0.24 to 0.39)<0.0010.30 (0.12 to 0.47)0.0010.33 (0.18 to 0.49)<0.0010.22 (0.18 to 0.49)<0.001
Concurrent†0.60 (0.48 to 0.71)<0.0010.52 (0.28 to 0.76)<0.0010.62 (0.40 to 0.84)<0.0010.60 (0.40 to 0.80)<0.001
Total consultationsComplicating*1.19 (1.15 to 1.24)<0.0011.23 (1.11 to 1.35)<0.0011.17 (1.08 to 1.26)<0.0011.06 (1.03 to 1.10)<0.001
Concurrent†1.21 (1.14 to 1.28)<0.0011.20 (1.05 to 1.37)0.0081.23 (1.10 to 1.36)<0.0011.16 (1.10 to 1.22)<0.001
  • β indicates increase in outcome variables per unit increase in complicating or concurrent comorbidity (main determinants); CI, confidence interval.

  • All analyses are adjusted for age, sex and HbA1c.

  • *Also adjusted for concurrent comorbidities;

  • †Also adjusted for complicating comorbidities.

  • GP, general practice; DNS, diabetes nurse specialist practice; MS medical specialist practice.